Shares of Traws Pharma, Inc. (NASDAQ:TRAW – Get Free Report) have been given an average recommendation of “Reduce” by the five brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $1.00.
TRAW has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Traws Pharma in a report on Wednesday, August 26th. HC Wainwright reiterated a “neutral” rating and set a $1.00 price objective on shares of Traws Pharma in a research note on Tuesday, August 18th.
Read Our Latest Stock Report on Traws Pharma
Traws Pharma Trading Up 11.1%
Traws Pharma stock opened at $0.25 on Thursday. Traws Pharma has a 1-year low of $0.22 and a 1-year high of $3.23. The firm has a market capitalization of $3.84 million, a price-to-earnings ratio of -0.14 and a beta of 1.67. The firm has a 50 day simple moving average of $0.44 and a 200 day simple moving average of $1.09.
Traws Pharma (NASDAQ:TRAW – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.18. On average, equities research analysts forecast that Traws Pharma will post -1.20 EPS for the current year.
Traws Pharma Company Profile
Traws Pharma, Inc. is a clinical-stage biotechnology company focused on developing antiviral medicines for respiratory viral infections, including influenza and COVID-19. The company’s approach includes developing therapies designed to act against viral replication and host-cell pathways involved in disease progression. Traws Pharma’s pipeline includes zapnometinib, an investigational oral host-directed antiviral designed to inhibit the MEK signaling pathway, which may support treatment across multiple strains of influenza and coronaviruses.
See Also
- Five stocks we like better than Traws Pharma
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
